Sorafenib Tosylate CAS 475207-59-1 Purity ≥99.0% (HPLC) API Factory High Quality
Commercial Supply Sorafenib Tosylate and Related Intermediates:
Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| Chemical Name | Sorafenib Tosylate |
| Synonyms | Nexavar; 4-[4-[3-[4-Chloro-3-(Trifluoromethyl)phenyl]ureido]phenoxy]-N-Methylpicolinamide 4-Methylbenzenesulfonate; 4-[4-[[4-Chloro-3-(Trifluoromethyl)phenyl]carbamamido]phenoxy]-N-Methyl-2-Pyridinecarboxamide 4-Methylbenzenesulfonate; BAY 43-9006 Tosylate |
| CAS Number | 475207-59-1 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C21H16ClF3N4O3.C7H8O3S |
| Molecular Weight | 637.03 |
| Melting Point | 225.0 to 230.0℃ |
| Sensitive | Air Sensitive, Heat Sensitive |
| Solubility | Soluble in Water (<1 mg/ml) at 25℃, DMSO (127 mg/ml ) at 25℃, and Ethanol (<1 mg/ml ) at 25℃ |
| Shipping Conditions | Cool & Dry Place (2~8℃), Protect from Light |
| COA & MSDS | Available |
| Shelf Life | 2 Years if Stored Properly |
| Brand | Ruifu Chemical |
| Item | Specifications | Results |
| Appearance | Light Yellow or White Powder | Complies |
| Purity / Analysis Method | ≥99.0% (HPLC) | 99.8% |
| Melting Point | 225.0~230.0℃ | Complies |
| Heavy Metals | ≤10ppm | <10ppm |
| Loss on Drying | ≤0.50% | 0.12% |
| Residue on Ignition | ≤0.20% | 0.10% |
| Any Single Impurity | ≤0.50% | Complies |
| Total Impurities | ≤0.50% | Complies |
| NMR Spectrum | Conforms to Structure | Complies |
| Test Standard | Enterprise Standard | Complies |
| Usage | Sorafenib Tosylate (CAS: 475207-59-1) in the treatment of RCC & HCC | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in a tightly closed container. Store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
Risk Codes 36/37/38 - Irritating to eyes, respiratory system and skin.
Safety Description S28 - After contact with skin, wash immediately with plenty of soap-suds.
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Sorafenib Tosylate (CAS: 475207-59-1) is a new type of multi-target antitumor drug, was developed by the German Bayer Pharmaceuticals, and displayed expansive antitumor activity in preclinical animal tests. Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and HCC. Sorafenib Tosylate can simultaneously affect tumor cells and tumor blood vessels. It has a double antitumor effect: it can block the cell signal transduction pathways mediated by RAF/MEK/ERK to directly inhibit tumor cell growth, while also inhibiting VEGF and platelet derived growth factors (PDGF) receptors to prevent the formation of new tumor blood vessels, thus indirectly inhibiting tumor cell growth.
Sorafenib Tosylate, trade name Nexavar, it was first developed by Bayer Pharmaceuticals in Germany. Sorafenib Tosylate is a multi-kinase inhibitor that can be used to treat diseases such as cancer. In December 2005, it was approved by the US FDA as a first-line drug for the treatment of advanced renal cancer. In August 2009, it was officially listed in China with the approval of the State Food and Drug Administration.
Sorafenib Tosylate are tyrosine kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitors, acting simultaneously on Raf-1,wtBRAF and V599EBRAF, with IC50 of 6 nM, 22 nM and 38 nM, respectively.
Sorafenib Tosylate can simultaneously inhibit a variety of kinases that exist on the cell and the cell surface, including RAF kinase, vascular endothelial growth factor receptor-2 (VEGFR-2), vascular endothelial growth factor receptor-3 (VEGFR-3), platelet-derived growth factor receptor-β (PDGFR-β), KIT and FLT-3. It can be seen that sorafenib toluenesulfonate has dual anti-tumor effects. On the one hand, it can directly inhibit tumor growth by inhibiting RAF/MEK/ERK signaling pathway; on the other hand, it can inhibit VEGFR and PDGFR. And block the formation of tumor neovascularization, indirectly inhibit the growth of tumor cells. Sorafenib Tosylate is by far the most effective drug for the treatment of progressive liver cancer by systemic administration, and will likely become the new standard drug for the treatment of this disease.
Sorafenib Tosylate once-daily oral administration of human tumor animal transplantation models showed a wide range of anti-tumor activity, including colon cancer, non-small cell carcinoma, breast cancer, melanoma, pancreatic cancer, leukemia and ovarian cancer and mouse renal cell carcinoma model, RENCA model.
